Glenmark infringed Bayer’s Finacea patent, says Federal Circuit
The US Court of Appeals for the Federal Circuit ruled that Glenmark Pharmaceuticals infringed a Bayer Healthcare patent for the rosacea treatment Finacea.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
13 May 2016 The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.
13 May 2016 The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.
13 May 2016 The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.